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for ZIKV in mice.

Highlights
d

TAM receptors are not essential for ZIKV infection in mice

d

TAM receptors are not required for mother-to-fetus
transmission in IFNAR-blocked mice

d

ZIKV tropism in the placenta and brain does not depend on
TAM receptors

d

Murine Axl is capable of facilitating ZIKV infection in human
cells in vitro

Hastings et al., 2017, Cell Reports 19, 558–568
April 18, 2017 ª 2017 The Author(s).
http://dx.doi.org/10.1016/j.celrep.2017.03.058

Cell Reports

Article
TAM Receptors Are Not Required
for Zika Virus Infection in Mice
Andrew K. Hastings,1,8 Laura J. Yockey,2,8 Brett W. Jagger,3,8 Jesse Hwang,1 Ryuta Uraki,1 Hallie F. Gaitsch,1
Lindsay A. Parnell,5 Bin Cao,5 Indira U. Mysorekar,5,6 Carla V. Rothlin,2 Erol Fikrig,1,7,* Michael S. Diamond,3,4,5,6,*
and Akiko Iwasaki2,7,9,*
1Section

of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
of Immunobiology, Yale University School of Medicine, New Haven, CT 06520, USA
3Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, Saint Louis, MO 63110, USA
4Department of Molecular Microbiology, Washington University School of Medicine, Saint Louis, MO 63110, USA
5Department of Obstetrics and Gynecology, Washington University School of Medicine, Saint Louis, MO 63110, USA
6Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA
7Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA
8Co-first author
9Lead Contact
*Correspondence: erol.fikrig@yale.edu (E.F.), diamond@wusm.wustl.edu (M.S.D.), akiko.iwasaki@yale.edu (A.I.)
http://dx.doi.org/10.1016/j.celrep.2017.03.058
2Department

SUMMARY

Tyro3, Axl, and Mertk (TAM) receptors are candidate entry receptors for infection with the Zika virus
(ZIKV), an emerging flavivirus of global public health
concern. To investigate the requirement of TAM receptors for ZIKV infection, we used several routes
of viral inoculation and compared viral replication in
wild-type versus Axl / , Mertk / , Axl / Mertk / ,
and Axl / Tyro3 / mice in various organs. Pregnant
and non-pregnant mice treated with interferon-a-receptor (IFNAR)-blocking (MAR1-5A3) antibody and
infected subcutaneously with ZIKV showed no reliance on TAMs for infection. In the absence of
IFNAR-blocking antibody, adult female mice challenged intravaginally with ZIKV showed no difference
in mucosal viral titers. Similarly, in young mice that
were infected with ZIKV intracranially or intraperitoneally, ZIKV replication occurred in the absence of
TAM receptors, and no differences in cell tropism
were observed. These findings indicate that, in
mice, TAM receptors are not required for ZIKV entry
and infection.
INTRODUCTION
Zika virus (ZIKV) is an emerging, positive-sense, enveloped flavivirus that is primarily transmitted by the Aedes species of
mosquitoes. Although it was first discovered in Africa in 1947
(Dick, 1952; Dick et al., 1952), ZIKV has gained worldwide attention recently after an outbreak in the Americas and an association with severe birth defects, including microcephaly and
congenital malformations. Although mosquito transmission explains most of the ZIKV infections in humans, (Li et al., 2012), it
has become apparent during the most recent outbreaks that,

in contrast to other flaviviruses, ZIKV can also be transmitted
by sexual contact (World Health Organization, 2016).
It is believed that 80% of ZIKV infections are asymptomatic
(Duffy et al., 2009), with the majority of others presenting with a
relatively mild self-limiting febrile illness that can be accompanied by rash, myalgia, conjunctivitis, and headache (Bearcroft,
1956; Simpson, 1964). However, the new outbreaks have been
linked to more severe disease, including Guillain-Barre syndrome (GBS), marked by subacute flaccid paralysis (Ioos
et al., 2014; Oehler et al., 2014) in adults, and congenital
malformations and neurological syndromes in newborns. Birth
defects have been attributed to this virus in at least 28 countries (Schuler-Faccini et al., 2016; Ventura et al., 2016; World
Health Organization, 2016). While many of the acute clinical
manifestations of ZIKV are seen with closely related flaviviruses, the ability of ZIKV to persist in semen, transmit through
sexual contact, and cause birth defects is unexpected. One
possible explanation for the differences in the clinical manifestations of ZIKV compared with related viruses is altered
tropism. To this end, identification of the entry receptor(s) for
ZIKV is critical to understanding the tropism and pathogenesis
of this virus and could promote the development of novel therapies that block or disrupt infection.
Replication of ZIKV has been described in a variety of tissues
in the host, including the CNS (Tang et al., 2016a), saliva (Musso
et al., 2015), blood (Musso et al., 2016), urine (Zhang et al., 2016),
and semen (Atkinson et al., 2016). Tropism of ZIKV for cells in the
brain (Li et al., 2016) and the testes (Govero et al., 2016; Ma et al.,
2016) leads to apoptosis of critical cell types in these organs. In
addition, like other flaviviruses, dendritic cells and macrophages
in the skin and other tissues are thought to be a primary target for
replication of ZIKV (Hamel et al., 2015; Jurado et al., 2016; Wu
et al., 2000). Cell-culture studies investigating the entry factors
for other important flaviviruses, including dengue virus (DENV),
West Nile virus (WNV), and Japanese encephalitis virus (JEV),
have proposed a variety of proteins, but data supporting their
function in vivo are inconclusive or non-existent. Two families
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of proteins with the most evidence for augmenting flavivirus
infection are the C-type lectins (Dejnirattisai et al., 2011; Tassaneetrithep et al., 2003; Vega-Almeida et al., 2013) and the
phosphatidylserine receptors, T cell immunoglobulin and mucin
domain (TIM) and Tyro3, Axl, and Mertk (TAM) (Kuadkitkan et al.,
2010; Meertens et al., 2012). One member of the TAM family of
receptor tyrosine kinases (RTKs), Axl, has been implicated as
an entry receptor for ZIKV (Meertens et al., 2017).
Axl is expressed at high levels in several cell types that are susceptible to ZIKV infection, (Lemke and Burstyn-Cohen, 2010; Ma
et al., 2016; Nowakowski et al., 2016; Rothlin et al., 2015; Tabata
et al., 2016) and in vitro evidence in cell lines and human primary
cells (Hamel et al., 2015; Liu et al., 2016; Meertens et al., 2017; Retallack et al., 2016; Savidis et al., 2016) using gene silencing,
ectopic expression, chemical inhibitors, or blocking antibodies
supports the hypothesis that the virus uses Axl either to enter cells
or as a signaling receptor to enhance infection. However, recent
data using CRISPR-Cas9-based gene editing of Axl in human
neural progenitor cells (NPCs) and cerebral organoids questioned
this conclusion, as loss of Axl expression did not impact ZIKV
infectivity (Wells et al., 2016). Moreover, members of our group
have shown that ZIKV infection of brain, eyes, and testes (Govero
et al., 2016; Miner et al., 2016b) in mice treated with a type I interferon (IFN) receptor blocking antibody, MAR1-5A3 (a-IFNAR [IFN
a receptor] antibody), is not dependent on TAM receptors Axl and
Mertk. The TAM family of transmembrane proteins contain an
extracellular, a transmembrane, and a conserved intracellular
tyrosine kinase domain and bind the ligands Gas6 and Protein
S, which recognize phospatidylserine moieties on dying cells or
on enveloped viruses (Lemke and Burstyn-Cohen, 2010; Shimojima et al., 2007). TAM receptors have many cellular functions,
including natural killer (NK) cell differentiation, clearance of
apoptotic debris, and innate immune modulation (Bosurgi et al.,
2013; Caraux et al., 2006; Carrera Silva et al., 2013; Paolino
et al., 2014). TAM receptors are induced through the type I IFN
pathway and limit an overabundant inflammatory response by inhibiting signaling downstream of the Toll-like receptors (TLRs)
(Rothlin et al., 2007). In some cells (e.g., dendritic cells), TAM receptor anti-inflammatory signaling requires a physical interaction
with IFNAR1 (Rothlin et al., 2007). As type I IFN signaling is critical
for the control of ZIKV infection (Lazear et al., 2016) and the function and expression of some TAM receptors, an analysis of the role
of TAM receptors on ZIKV infectivity must consider the TAM
receptor-IFN signaling axis. In this study, we compare ZIKV infection and pathogenesis in wild-type (WT) and TAM-receptor-deficient mice through different routes of infection and analysis.
RESULTS
Axl and Mertk Are Not Required for Transplacental
Transmission, Replication in Pregnant Mice, or
Replication in Fetuses
A mouse model of transplacental infection of fetuses was
described using an a-IFNAR-blocking antibody to facilitate
susceptibility of pregnant C57BL/6 wild-type (WT) mice to ZIKV
infection. Fetuses from ZIKV-infected dams treated with the
IFNAR-blocking antibody become infected and exhibit an intrauterine growth defect compared to control mice (Miner et al.,

2016a). We utilized this pregnancy model to determine whether
Axl or another TAM receptor, Mertk, was involved in the transmission of ZIKV through the transplacental route or in replication of
the virus in fetal tissues. TAM receptors are expressed to varying
levels on several relevant cells, including placental trophoblasts,
fetal endothelial cells, Hofbauer macrophages, and fetal neuroprogenitor cells (Nowakowski et al., 2016; Tabata et al., 2016).
Pregnant WT, Axl / , Mertk / , and Axl / Mertk / dams who
had been mated with the respective WT or TAM knockout (KO)
sires were treated with a-IFNAR-blocking antibody and inoculated subcutaneously with 103 focus-forming units (FFUs) of a
Brazilian strain (Paraiba 2015) of ZIKV on embryonic day (E) 6.5,
and both maternal tissue and fetal tissue were harvested on
E13.5 for analysis of levels of viral RNA by qRT-PCR. In the pregnant dams, we observed no difference in ZIKV RNA levels in the
brains and spleens of WT, Axl / , and Mertk / mice; a significant
increase in serum ZIKV titer was noted in Axl / dams (Figure 1A).
Analogously, the levels of ZIKV RNA in the brains of a-IFNARtreated non-pregnant female Axl / mice were similar to those
in WT mice (Figure S1).
To assess the role of TAM receptors in promoting transplacental transmission, we analyzed viral RNA in the placenta and
the heads of fetal mice. We observed no significant differences
in ZIKV infection between WT, Axl / , and Axl / Mertk / fetal
heads and only a modest increase in viral titers in Mertk / placentas as compared to WT (Figure 1B). In addition, we saw no
difference in the size of ZIKV-infected fetuses between groups
(Figure 1C). To determine whether TAM receptors influenced
the tropism of ZIKV infection in the placenta, we performed
in situ hybridization (ISH) with ZIKV-specific RNA probes. The
placenta is composed of two layers: the junctional zone,
composed of spongiotrophoblasts and invasive glycogen cells;
and the labyrinth zone composed of cytotrophoblast and syncytial trophoblasts and fetal-derived blood vessels (Coan et al.,
2005). At E13.5, ISH for ZIKV RNA revealed similar staining patterns, with scattered positive cells in the junctional zone and a
lack of appreciable positivity in the labyrinth zone; similar
numbers of positive cells were noted in placentas harvested
from WT, Axl / , and Axl / Mertk / mice (Figure S2). Together,
these data demonstrate that neither Axl nor Mertk are required
for ZIKV infection of mice treated with IFNAR-blocking antibody.
Additionally, transplacental transmission and replication of the
virus in the placenta and the fetus can occur independently of
the expression of Axl or Mertk receptors.
Replication of ZIKV in the Vaginal Tract of Virgin Mice
Does Not Require Axl Expression
As the expression of AXL is induced by type I IFN signaling (Scutera et al., 2009), and its signaling function in some cells requires
IFNAR1 expression (Rothlin et al., 2007), type I IFN signaling may
be necessary for Axl to enhance flavivirus infection (Bhattacharyya et al., 2013). Intravaginal infection of ZIKV allows local viral
replication in the vaginal tract, even in WT mice (Khan et al.,
2016; Yockey et al., 2016). This model allowed us to investigate
whether ZIKV infection required Axl expression under conditions
when type I IFN signaling remained intact. Virgin WT or Axl /
mice were treated with Depo-Provera to maintain the diestruslike phase, when mice are most susceptible to vaginal ZIKV
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Figure 1. ZIKV Infection of Maternal and
Fetal Tissues Is Similar in WT, Axl / ,
Mertk / , and Axl / Mertk / Mice

A

B

C

infection (Tang et al., 2016b; Yockey et al., 2016). Animals were
then inoculated intravaginally with 1.5 3 105 plaque-forming
units (PFUs) of ZIKV FSS13025 (Cambodia 2010). Vaginal
washes were collected daily, and RNA was isolated. ZIKV RNA
levels in the vaginal washes persisted through 6 days post-infection in both WT and Axl / mice (Figure 2). No significant differences were observed between the groups except on day 4,
when ZIKV levels in the Axl / mice dropped slightly (p = 0.02);
nonetheless, comparable levels of viral RNA were observed in
WT and Axl / mice at day 5 (Figure 2). These data indicate
that Axl is not required for ZIKV infection in the vaginal tract.
ZIKV Replication in 1-Week-Old Neonatal Mice after
Intraperitoneal Inoculation Is Axl Independent
Neonatal mice younger than 7 days old are susceptible to ZIKV
infection via the intraperitoneal route without IFNAR blockade
(Dick, 1952; Lazear et al., 2016; Manangeeswaran et al., 2016).
We used this model to determine whether the TAM receptors
are involved in replication or trafficking of ZIKV from the peri-
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Pregnant WT, Axl / , Mertk / , and Axl / Mertk /
dams were treated with 2 mg of a-IFNAR-blocking
antibody on embryonic day (E) 5.5 and inoculated
subcutaneously with 103 FFUs of the Brazilian
strain of ZIKV on E6.5.
(A) Serum, brain tissue, and splenic tissue from
ZIKV-infected pregnant dams were collected at
E13.5 and assessed for viral titer by qRT-PCR.
ZIKV titers in Axl / sera were higher than those in
WT dams (15-fold, *p = 0.0372 by Kruskal-Wallis
with Dunn’s multiple comparisons test), but serum
titers in Mertk / dams were not significantly
different from those in WT. No significant differences in spleen or brain titers were found. n = 4
pregnant dams for WT, 4 for Axl / , 2 for Mertk / ,
and 8 for Axl / Mertk / . eq, equivalent.
(B) Fetal heads and placental tissue were also
collected at E13.5 and assessed for viral titer
by qRT-PCR. No significant differences in viral
burden were observed in fetal heads. In placentas
likewise, no significant differences in viral burden
were seen, except in Mertk / placentas, which
exhibited a 7-fold increase in viral burden as
compared to WT (*p = 0.0196, Kruskal-Wallis with
Dunn’s multiple comparisons test). n = 12 for WT,
20 for Axl / , 8 for Mertk / , and 32 for
Axl / Mertk / . The gray dashed line indicates the
limit of detection.
(C) Fetal size at E13.5 was measured as crownrump length (CRL) 3 occipita-frontal (OF) diameter
expressed as square millimeters. n = 4–10 per
indicated group. ns, not significant by KruskalWallis with Dunn’s multiple comparisons test.
See also Figures S1 and S2.

phery to the CNS. Seven-day-old WT,
Axl / , Mertk / , and Axl / /Mertk /
mice were inoculated with 104 PFUs of
the Brazilian strain (Paraiba 2015) of
ZIKV. After 7 days, these animals were euthanized, spleens
and brains were harvested, and ZIKV burden was measured using qRT-PCR. Viral burden was higher in the spleen and brain of
Axl / /Mertk / -infected mice, but no other significant differences were detected in the brain or spleen between any of these
groups (Figure 3), showing that Axl and Mertk are not required for
replication of ZIKV in lymphoid tissue or spread to the brain, even
in the presence of an intact type I IFN signaling system.
ZIKV Replication and Tropism after Intracranial
Inoculation of ZIKV Is Not Affected by the Absence of
Axl, Mertk, and Tyro3
To investigate the requirement of Axl, Mertk, and Tyro3 directly in
the brain, again without the need for IFNAR blockade, we used a
model of intracranial inoculation of 10-day-old mice (Dick, 1952).
This method has an added benefit of bypassing any role that TAM
receptors play in replication in other tissues or transmission to the
brain (Miner et al., 2015). Ten-day-old WT, Axl / /Tyro3 / , and
Axl / /Mertk / mice were inoculated with 106 PFUs of ZIKV

Figure 2. WT and Axl / Mice Support
Similar ZIKV Levels after Intravaginal
Infection
Fourteen- to 16-week-old WT and Axl / female
mice were treated with Depo-Provera and inoculated intravaginally with 1.5 3 105 PFUs of
Cambodia strain ZIKV and daily vaginal washes
were collected. Titers were determined by RNA
isolation of vaginal washes, and levels were
determined by qRT-PCR. ZIKV levels on day 4
were significantly lower in Axl / mice (*p = 0.026)
but were not significantly different between WT
and Axl / at any other time point. Data shown are
pooled from two independent experiments (n = 6
per group for infected; n = 5 per group for uninfected). Gray dashed line indicates the limit of
detection.

MEX2-81 (Mexico 2016) via an intracranial route and monitored
for 7 days. Brains were harvested at day 5 and day 7 post-infection, the peak of viral infection, and assessed for viral replication
using both qRT-PCR and plaque assays. Groups showed no significant differences in growth rates, until day 7 when all three infected groups exhibited a decline in weight as compared to uninfected controls (Figure 4A). Viral titers in the brain were not
significantly different in the WT and KO groups as measured by
RNA levels (Figure 4B) or infectious virus (Figure 4C). To determine whether TAM receptor expression affected the cellular
tropism of ZIKV infection in the brain, we performed immunohistochemical analysis. We co-stained for ZIKV infection with antigenic markers for neurons (neuronal nuclei; NeuN), astrocytes
(glial fibrillary acidic protein; GFAP), and microglia (ionized calcium-binding adapter molecule 1; Iba1) at days 5 and 7 postinfection. Our data suggest that the majority of ZIKV infection
localizes to neurons on day 5 (Figure 5), whereas at day 7,
some microglia also co-stain with ZIKV antigen (Figure 5). All images shown are from the cortex, but staining was also seen in the
hippocampus for most samples and in the cerebellum in some
samples. Notably, no differences were observed in ZIKV antigen
staining or co-localization with cells from WT and TAM-receptor-deficient mice. These data show that pathogenesis and viral
replication is equal in WT, Axl / /Tyro-3 / and Axl / /Mertk /
mice after intracranial infection of ZIKV.
Mouse Axl Is Sufficient to Restore ZIKV Infection of
Human Cells Lacking Axl
One possibility for the discrepancy between our studies, which
show no role for TAM receptors in mouse models of ZIKV infection, and the previously published in vitro studies showing a
requirement for TAM receptors in infection of different human
cell types, is that there may be a species-specific incompatibility
between ZIKV’s interaction (via Gas6) with human and mouse
Axl. To directly address this, we used transcomplementation
studies to investigate whether mouse Axl is sufficient to restore
ZIKV infection in human cells lacking Axl. Consistent with previous studies (Hamel et al., 2015; Liu et al., 2016; Meertens et al.,
2017; Retallack et al., 2016; Savidis et al., 2016), we used fluo-

rescent microscopy to show that HeLa cells in which Axl has
been gene edited using CRISPR-Cas9 were markedly less susceptible to ZIKV infection (Figures 6A and 6B), and we validated
these findings using flow cytometry (Figure 6C). Expression of
mouse Axl using a retroviral vector restored ZIKV infection of human Axl-deficient cells (Figures 6A–6C). The presence of human
and mouse Axl was confirmed by western blotting (Figure 6D).
These data show that mouse Axl is capable of mediating ZIKV
infection in human cells and that the dispensability of Axl in
mice is unrelated to its ability to serve as an entry receptor.
DISCUSSION
TAM receptors are considered candidates for a ZIKV entry receptor, based largely on studies in cell culture or co-localization analysis in vivo. By performing comparative infection studies in WT and
TAM receptor KO mice, we demonstrated that TAM receptors are
not required for ZIKV infectivity through subcutaneous, transplacental, vaginal, or intracranial routes of infection. ZIKV replication
is unaffected by the lack of these receptors in tissues including the
spleen, placenta, vagina, and brain. We also show that the cellular
targets in the brain and placenta are similar, regardless of the
absence of the TAM receptors. These findings indicate that, in
mice, TAM receptors are not required for ZIKV infection.
Several previous studies show that inhibition of Axl in vitro in human cells blocks ZIKV infection (Hamel et al., 2015; Liu et al., 2016;
Meertens et al., 2017; Retallack et al., 2016; Savidis et al., 2016).
Specifically, CRISPR KO of Axl results in reduced ZIKV infection
in human cervical adenocarcinoma cells (HeLa) (Savidis et al.,
2016), the human glioblastoma line (U87) (Retallack et al., 2016),
the human microglial cell line (CHME3) (Meertens et al., 2017),
and human embryonic kidney cells (293T) (Liu et al., 2016); and
small interfering RNA (siRNA) knockdown of Axl results in reduced
ZIKV infection in human alveolar basal epithelial carcinoma cells
(A549) (Hamel et al., 2015). Based on these results, we speculated
that the mechanisms that underlie the dispensability of TAM receptors in ZIKV infection in mice in vivo include the following: (1)
the inability of mouse TAM to serve as ZIKV entry receptors; (2)
the existence of other entry receptors in mice that are not
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Figure 3. ZIKV Titers in Intraperitoneal
Infection of 7-Day-Old WT, Axl / , and
Mertk / Mice Are Similar and Higher in
Axl / Mertk / Mice
One-week-old mice were infected with 104 FFUs
of Brazil strain ZIKV by intraperitoneal injection.
Viral replication in spleen (left) and brain (right) was
quantified 1 week post-infection by qRT-PCR. 10fold more ZIKV RNA was found in Axl / Mertk /
spleens than in WT spleens, and 4-fold
more was found in Axl / Mertk / brains than in
WT. Viral burdens in Axl / Mertk / spleens
and brains were also higher than in Axl / and
Mertk / mice. Symbols represent focus-forming
equivalents per gram of ZIKV RNA for individual
animals; solid line represents median, and gray
dashed line represents limit of detection. For
spleen: *p = 0.0161; **p = 0.002; ***p = 0.0001.
For brain: **p = 0.0038 (Axl / Mertk / versus
Mertk / ); **p = 0.0074 (Axl / Mertk / versus
Axl / ); and ****p < 0.0001 (Axl / Mertk /
versus WT) as calculated using one-way ANOVA
with Tukey’s multiple comparisons test.

expressed by human cells; and (3) human cells in vivo also have
redundant entry receptors, although human cell lines in vitro fail
to recapitulate the expression of the entire spectrum of viral entry
receptors present in their in vivo counterparts.
In order to determine whether mouse Axl is capable of serving
as a viral entry receptor, we performed a transcomplementation
study in HeLa cells. We found that endogenous human Axl is
required for ZIKV infection, as previously reported (Savidis
et al., 2016), and that mouse Axl was sufficient to restore infection in HeLa cells lacking human Axl. Thus, these results eliminated the possibility that mouse Axl fails to serve as a viral receptor for ZIKV. The second possibility, as discussed earlier, is that
key target cells for ZIKV infection in mice, but not humans, express additional receptors (e.g., TIM-1 or other phosphatidylserine receptors such as CD300a; Carnec et al., 2015), allowing
infection to occur in the absence of TAM receptors due to functional redundancy. This possibility requires generating multigene KO mice in the future. The third possibility is that the human
cells in vivo also have multiple entry receptors for ZIKV but that
human cell lines in vitro fail to recapitulate the expression of
the entire spectrum of viral entry receptors. Many of the experiments suggesting a key entry role for ZIKV were performed in cell
lines that may not fully represent the patterns of receptor expression in vivo on primary cells (Liu et al., 2016; Retallack et al.,
2016; Savidis et al., 2016). It is also possible that the differences
in type I IFN signaling after ZIKV infection in mice versus humans
may be masking an important role for Axl in infection in mice.
Meertens et al. suggest that ZIKV exploits Axl’s ability to suppress the type I IFN response after infection (Meertens et al.,
2017), and most mouse models for ZIKV infection require the
ablation of IFN signaling due to an impaired ability of the virus
to suppress mouse, but not human, IFN response (Grant et al.,
2016). To address this, we included models that do not require
suppression of the type I IFN response among the models that
we tested. However, ZIKV may preferentially be infecting cells
that have an impaired ability to produce type I IFN, potentially
minimizing the effects of Axl (Khan et al., 2016; Kreit et al., 2014).
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It remains possible that Axl, Mertk, or Tyro3 are entry receptors in specific cells that we did not capture with the infection
routes that were tested in our study. We consider this unlikely,
given the various routes of infection used including subcutaneous, transplacental, intravaginal, intraperitoneal, and intracranial
ZIKV administration. We did not observe any differences in viral
titers or tropism in the mouse in various organs tested. Particularly, in our intracranial infection model, neurons were infected,
but astrocytes were not. In the human developing brain, Axl is
required for ZIKV infection in astrocytes but not in NPCs (Meertens et al., 2017). In the present study, intracranial infection of
young WT mice showed no infection of astrocytes. However,
our results showing no differences in infection of neurons in
WT versus Axl KO mice are consistent with a lack of role of Axl
in infection of NPCs or brain organoid cultures (Meertens et al.,
2017; Wells et al., 2016).
Independent of its possible function as an entry receptor, TAM
receptors can have important roles in the pathogenesis of viral
infections through additional mechanisms. For example, Mertk
and Axl promote blood-brain-barrier integrity and protect mice
against pathology after neuroinvasive WNV infection (Miner
et al., 2015). Axl / mice have increased lethality and delayed virus clearance after influenza and WNV infection due to impaired
priming of the adaptive immune response by DCs (Schmid et al.,
2016). Mertk and Axl are also essential for many aspects of microglial function and the ability of microglia to clear apoptotic
cells in the adult brain (Fourgeaud et al., 2016). Our results indicate that Axl and Mertk may not be necessary for the clearance
of ZIKV-infected cells, as we showed that mice deficient in Axl
and Mertk had similar colocalization between ZIKV antigen and
microglia as that of the WT mice, suggesting phagocytosis by
the microglia, at later time points of infection. However, it is unclear whether this represents infection of these cells or the clearance of dead cell debris from infected neurons.
Overall, the data presented here suggest that other, as yet unidentified, receptors may have redundant roles for ZIKV entry
and infection. Finding the relevant entry receptors will be
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Mice Results in Similar Weight Loss and Viral Titers

Ten day-old WT, Axl / Mer / , and Axl / Tyro3 / mice were inoculated intracranially with 106 PFUs of Mexico strain ZIKV.
(A) Weights were measured daily after infection with ZIKV. Data are expressed as percentages of the average original body weight; error bars represent the SEM
(n = 4–12 per group).
(B and C) At days 5 and 7 post-infection (5 and 7 dpi, respectively), brains were harvested and assessed for ZIKV replication using (B) qRT-PCR and (C) plaque
assays. Data shown are the result of two pooled independent experiments (n = 4–8 per group). Significance was calculated using a one-way ANOVA with a post
hoc Tukey test. Error bars represent the SEM. n.s., not significant.

essential for a more complete understanding of ZIKV biology and
tropism. Given the reported overlap between Axl expression and
ZIKV tropism, it is possible that the entry receptor expression is
coincident to Axl expression in such cell types. These findings
pose the question as to whether there is similar redundancy in
ZIKV entry in humans in vivo. Pharmacological agents that
disrupt ZIKV binding to a bona fide entry receptor could be an
effective strategy to prevent or minimize infection.
EXPERIMENTAL PROCEDURES
Ethics Statement
All experiments were performed in accordance with guidelines from the
Guide for the Care and Use of Laboratory Animals of the NIH. Protocols
were reviewed and approved by the Institutional Animal Care and Use
Committee (IACUC) at Yale University School of Medicine (assurance
number A3230-01) and Washington University School of Medicine (assur-

ance number A3381-01). Every effort was made to reduce distress in
animals.
Viruses, Cell Lines, and Titration
Vero cells (ATCC) were maintained in DMEM containing 10% fetal bovine
serum (FBS) and antibiotics at 37 C with 5% CO2 and have been routinely
confirmed to be mycoplasma free. Aedes albopictus midgut C6/36 cells
were grown in DMEM supplemented with 10% FBS, 1% tryptose phosphate,
and antibiotics at 30 C with 5% CO2 air atmosphere. Mexico and Cambodia
strains of ZIKV were obtained from the University of Texas Medical Branch
at Galveston’s World Reference Center for Emerging Viruses and Arboviruses
and propagated in C6/36 insect cells or Vero cells. Brazil ZIKV (Paraı́ba 2015)
was obtained from Steve Whitehead (NIH/National Institute of Allergy and Infectious Diseases). Viral titers were determined by utilizing plaque assays as
previously described (Jurado et al., 2016).
Mouse Experiments
Axl / , Mer / , Axl / Mer / , and Axl / Tyro3 / mice have previously been
published (Lu and Lemke, 2001), and we confirm by western blot on the brain
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Figure 5. WT, Axl

/

Mertk

/

, and Axl

/

Tyro3

/

Mice Show Similar ZIKV Tropism in the Brain after Intracranial Infection

Ten-day-old mice of indicated genotypes were inoculated intracranially with 106 PFUs of ZIKV Mexico. Brains were harvested 5 and 7 days post-infection (dpi).
ZIKV was stained using immune rat sera, as indicated in red, and co-stained for neurons (NeuN), astrocytes (GFAP), or microglia (Iba1), as indicated in green. All
images shown are from the cortex. Representative images from two to three brains per time point per group are shown. Scale bars, 100 mm.
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Figure 6. Mouse Axl Is Sufficient to Restore ZIKV Infectivity in HeLa Cells Lacking Human Axl
(A–D) WT HeLa, Axl KO HeLa, and Axl KO transcomplemented with murine Axl HeLa were infected with ZIKV (MOI = 1) or mock infected. At 24 hours post-infection (hpi),
cells were either fixed and probed with the anti-flavivirus E protein (4G2) antibody and AF488 secondary antibody and DAPI before imaging by fluorescent microscopy
(A and B) or harvested for flow cytometry analysis and probed using the same antibodies (C). Western blot using anti-Axl human- and mouse-specific antibody to show
presence or absence of Axl in each cell line (D). hAxl, human Axl; mAxl, mouse Axl. Scale bars, 100 mm. SSC, side scatter.

and spleen that our Axl / mice do not express Axl (Figure S3). Mice were bred
in a specific-pathogen-free facility at Yale University, Washington University,
or purchased (WT animals) from Jackson Laboratory. For the pregnancy
model, adult WT, Axl / , Mer / , and Axl / Mer / dams were treated with
2 mg of an anti-Ifnar1 blocking mouse monoclonal antibody (mAb) (MAR15A3) (Sheehan et al., 2006) by intraperitoneal injection prior to infection with
ZIKV. For intravaginal infection, 14- to 16-week-old female mice were injected
with Depo-Provera (GE Healthcare) 5 days prior to infection. Mucous from the

vaginal lumen was removed using a Calginate swab (Fisher Scientific), and
1.5 3 105 PFUs of Cambodian ZIKV in a volume of 10 mL was inoculated
into the vaginal lumen using a pipette (Yockey et al., 2016). Daily vaginal
washes were collected 1–6 days after infection by pipetting 50 mL PBS into
the vaginal lumen as previously described (Yockey et al., 2016). One-weekold suckling mice were infected with 104 FFUs of Brazil ZIKV in 50 mL of
PBS diluent by intraperitoneal injection. One week after infection, mice were
euthanized per animal study protocol, and brains and spleens were dissected
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and flash frozen prior to virological analysis as described in the following text.
To determine TAM receptors’ role in ZIKV replication in the brain, 10-day-old
mice were infected intracranially with 105 PFUs of MEX2-81 ZIKV in a volume
of 10 mL as previously described (Dick, 1952). Weights were measured daily for
1 week, and brains were harvested at day 5 and day 7 after infection. For intraperitoneal (IP) and intracranial (IC) infections, an equal mix of male and female
mice were used.

were used: anti-Iba1 (1:500; Wako Pure Chemicals Industries, #01919741), GFAP (1:500; Dako, #Z0334), and NeuN (1:50; Cell Signaling,
#24307). After rinsing with PBS, goat anti-rat secondary antibody conjugated to A594 (1:1,000; Life Technologies) and goat anti-rabbit antibody
conjugated to Alexa 488 (1:1,000; Life Technologies). Samples were
mounted in Prolong Gold containing DAPI (4’6’-diamidino-2-phenilindole)
(Life Technologies).

Organ Collection
ZIKV-infected animals were euthanized on day 5 or day 7 after infection. To
collect brain tissue in young mice, after euthanasia, heads were removed,
skin was split from the base of the skull and peeled away, sharp scissors
were inserted at the base of the skull, carefully cut dorsally over the top of
the head, and bone was opened to reveal brain. Scissors were slid under
the brain to sever brain from ligaments and spinal cord and lifted out. The right
and left hemispheres of the brain were separated, one was placed in 4%
paraformaldehyde (PFA) for histology, and the other was separated into two
equal parts, weighed, and placed in media for plaque assay or TRIzol for
RNA purification. For pregnancy harvests, pregnant dams were euthanized,
and maternal and fetal tissues were flash frozen and then weighed in preparation for later homogenization and extraction as described in the following text.

Axl CRISPR KO of HeLa Cells and Murine Axl Transcomplementation
The single-guide (sgRNA) sequence GGAGGTTACGGGGCTGCTGG was
cloned into lentiCRISPR v.2 (Addgene, #52961) (Sanjana et al., 2014), and
the resulting plasmid was transiently transfected into HeLa cells and selected
in puromycin (1 mg/mL) for 4 days. Clones were screened for Axl KO by immunoblot analysis, and a single clone was carried out for in vitro experiments. For
retroviral transcomplementation with murine Axl, a full-length open reading
frame (ORF) of mAxl was cloned into the EcoRI and BamHI restriction sites
of pLXSN. COS-1 cells were co-transfected with pLXSN-mAxl, pUMVC (Addgene, #8449), and pCMV-VSV-G (Addgene, #8454), and the retrovirus-containing supernatant was collected at 48 hr post-transfection. HeLa Axl KO cells
were transduced with retrovirus in the presence of polybrene (10 mg/mL) and
selected with G418 (750 mg/mL) for 10 days to obtain a pooled population of
mAxl-expressing cells. Axl protein expression was confirmed by human-specific (R&D Systems, #AF154) and mouse-specific (R&D Systems, #AF854) Axl
antibodies.

Viral Burden Analysis
Tissues were homogenized using ceramic beads in either 10% DMEM (plaque
assay), TRIzol, or PBS (qRT-PCR); homogenized tissue was centrifuged for
10 min at 13,000 3 rpm; and supernatant was transferred to new tubes. For
plaque assays, supernatant was incubated on Vero cell monolayers in
10-fold serial dilutions for 1 hr at 37 C and overlaid with a mixture of 2%
agarose and 23 media. 3 to 4 days post-infection, cells were fixed by 10%
formalin and stained with 0.005% amido black, and PFUs were counted. For
tissues, total RNA was extracted using the QIAGEN RNeasy Mini Kit and
reverse transcribed using the iScript cDNA Synthesis Kit (Bio-Rad) according
to manufacturer’s protocol. For pregnancy experiments, total RNA was
analyzed using one-step qRT-PCR on an Applied Biosystems (ABI) 7500
Fast instrument, as per previously published protocols and primer set, with
quantification accomplished via fit to concurrently run standard curve (Lanciotti et al., 2016; Lazear et al., 2016). IQ SYBR Green Supermix (Bio-Rad)
was used along with ZIKV-specific primers, and ZIKV replication was calculated using the 2 DDCT method normalized to b actin RNA. For vaginal
washes, ZIKV was detected using primers designed to NS5 (forward:
GGCCACGAGTCTGTACCAAA; reverse: AGCTTCACTGCAGTCTTCC), and
FFU-equivalent was determined by normalization to RNA prepared from virus
stock (Yockey et al., 2016).
RNA ISH
RNA ISH was performed using the RNAscope 2.5 HD-BROWN assay
(Advanced Cell Diagnostics) according to the manufacturer’s instructions
and as previously described (Govero et al., 2016). 4% PFA-fixed, paraffinembedded tissue sections were deparaffinized by incubating for 60 min at
60 C, and endogenous peroxidases were quenched with H2O2 for 10 min at
room temperature. Slides were then boiled for 15 min in RNAscope Target
Retrieval Reagents and incubated for 30 min in RNAscope Protease Plus Reagent prior to ZIKV RNA (Advanced Cell Diagnostics, catalog #467771), positive control Mus musculus Ppib gene (#313911), or negative control bacterial
gene dapB (#310043) probe hybridization and signal amplification. Sections
were counterstained with Gill’s hematoxylin and visualized by bright-field
microscopy.
Brain Sectioning and Immunostaining
Brains from intracranially infected mice were collected in 4% PFA (Electron
Microscopy Sciences) and fixed overnight at 4 C. After fixation, brains were
dehydrated in a sucrose gradient up to 30% sucrose, cut sagitally, and
embedded in OCT (optimal cutting temperature) compound. Sections
were washed with PBS, permeabilized, and blocked in buffer containing
2% donkey serum. The following primary antibodies were incubated overnight: for ZIKV staining, ZIKV-immune rat serum was used at 1:2,000
(van den Pol et al., 2017). For costaining, the following primary antibodies
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ZIKV Infection and Analysis of Axl KO and Murine Axl
Transcomplemented HeLa Cells
WT, Axl KO, and mouse Axl transcomplemented HeLa cells were infected with
ZIKV at an MOI of 1 and incubated at 37 C. After 24 hr, cells were trypsinized
and resuspended in ice-cold methanol to fix and permeabilize. Cells were
probed with 4G2, anti-flavivirus mouse monoclonal antibody, at 6.2 ng/mL,
followed by an Alexa Fluor 488 secondary antibody (1:2,000; Thermo Fisher
#A-11001), before analyzing on a 13-color Stratedigm flow cytometer. Flow
plots were generated using FlowJo.
Data Analysis
GraphPad Prism software was used to analyze all data. Log10-transformed
titers used for plaque assays, and either b-actin-normalized viral RNA or tissue-weight-normalized values were analyzed using one-way ANOVA and
post hoc Tukey test for multiple comparisons or Kruskal-Wallis and Dunn’s
multiple comparisons test, where appropriate, as indicated in figure legends.
A p value < 0.05 was considered statistically significant.
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